

To whom it may concern:

June 28, 2011

Company name: Fuji Pharma Co., Ltd. Representative: Hirofumi Imai, President & CEO (Securities Code: 4554) Contact: Toyoyuki Kamide Director and General Manager Administration Department +81-(0)3-3556-3344

Determination of Offer Price, Selling Price and Other Matters

Fuji Pharma Co., Ltd. ("the Company"), hereby announces that it has determined, as set forth below, the offer price (for a new issuance), the selling price (for a secondary offering) and other matters relating to the issuance of new shares and the secondary offering of shares of the Company, which were resolved at the meeting of the Board of Directors held on June 21, 2011.

1. Issuance of New Shares by Way of Offering (Public Offering)

(1)	Offer Price		per share	¥ 1,401
(2)	Total Offer Price			¥ 1,541,100,000
(3)	Issue Price		per share	¥ 1,328.75
(4)	Total Issue Price			¥ 1,461,625,000
(5)	Amount by Which Stated Capital and Legal Capital	The amount by which stated capital is to be increased		¥ 730,812,500
	Surplus Are To Be	The amount by which stated legal		· · · ·
	Increased	capital surplus is to be increased		¥ 730,812,500
(6)	Subscription Period	Wednesday, June 29, 2	2011 — Thurs	sday, June 30, 2011
(7)	Payment Date		Η	Friday, July 8, 2011

Note: The Underwriters will purchase the shares at the Issue Price and offer them at the Offer Price.

2. Secondary Offering of Shares (Secondary Offering by Way of Overallotment)

(1)	Number of Shares To Be			
	Sold			150,000 shares
(2)	Selling Price		per share	¥ 1,401
(3)	Total Selling Price			¥ 210,150,000
(4)	Subscription Period	Wednesday, June 29, 20	011 — Thursc	lay, June 30, 2011
(5)	Delivery Date		Mone	day, July 11, 2011

3. Issuance of New Shares by Way of Third-Party Allotment

(1)	Issue Price	·	per share	¥ 1,328.75
(2)	Total Issue Price		(Maximun	n) ¥ 199,312,500
(3)	Amount by Which Stated	The amount by which stated		
	Capital and Legal Capital	capital is to be increased	(Maximu	m) ¥ 99,656,250
	Surplus Are To Be	The amount by which stated legal		
	Increased	capital surplus is to be increased	(Maximu	m) ¥ 99,656,250
(4)	Subscription Period			
	(Subscription Date)		Wednesda	y, July 27, 2011
(5)	Payment Date		Thursda	ny, July 28, 2011

This press release has been prepared for the purpose of publicly announcing certain matters relating to the issuance of new shares and the secondary offering of the Company's shares and not for the purpose of soliciting investment or engaging in any other similar activity. Investors who intend to invest in the Company's shares are requested to make a determination at their own discretion by carefully referring to the prospectus regarding the issuance of new shares and the offering of the Company's shares, which must be prepared by the Company, as well as any corrections thereto (if revisions to any documents have been prepared).

<Reference>

- 1. Calculation of Offer Price and Selling Price
 - (1) Price Calculation Date and Price

	Price	Tuesday, June 28, 2011	¥ 1,445
(2)	Discount Rate		3.04%

- Syndicate Cover Transaction Period Friday, July 1, 2011 to Thursday, July 21, 2011
- 3. Use of proceeds

We estimate that the net proceeds from the Public Offering and the issuance of new shares by way of the Third-Party Allotment will be a maximum of \$1,645,937,500. By the end of September 2011, \$1,041,000,000 out of the total amount is scheduled to be used for capital investment toward "Building and structures" (\$149,000,000) and "Machinery and equipment as well as tools, furniture and fixtures" (\$892,000,000) for a factory for injection agents (Toyama Plant No. 5 production plant for injection agents). The rest of the proceeds will be partially appropriated to repayment funds for the loans from financial institutions, which were acquired for use as capital investment funds in this new plant and of which the repayment maturity will expire during the fiscal years ending September 2011 and September 2012.

Please refer to the Issuance of New Shares and Secondary Offering of Shares published on June 21, 2011 for the details of the facilities in which the intended investment will be made.

This press release has been prepared for the purpose of publicly announcing certain matters relating to the issuance of new shares and the secondary offering of the Company's shares and not for the purpose of soliciting investment or engaging in any other similar activity. Investors who intend to invest in the Company's shares are requested to make a determination at their own discretion by carefully referring to the prospectus regarding the issuance of new shares and the offering of the Company's shares, which must be prepared by the Company, as well as any corrections thereto (if revisions to any documents have been prepared).